Log inSign up
Hope Rugo
4,109 posts
user avatar
Hope Rugo
@hoperugo
san francisco
Joined August 2012
559
Following
11.6K
Followers
  • user avatar
    Hope Rugo
    @hoperugo
    Jun 5, 2022
    So moved by DB04, although I knew the data & treated pts. Our goal as oncologists is to improve outcome - and when we succeed so dramatically in the largest subset of the most common cancer in women, it is truly a profound moment. In memory of my mother, for all my patients ๐ŸŽ‰
  • user avatar
    Hope Rugo
    @hoperugo
    Jan 27, 2023
    Hot off the presses: FIRST ORAL SERD APPROVED FOR HR+/HER2- metastatic breast cancer! Elacestrant (Orserdu) approved for ESR1 mutated HR+ MBC after one line of ET. More options for our patients, one more step forward!
    40K
  • user avatar
    Hope Rugo
    @hoperugo
    Jan 9, 2022
    In the new year I honor wonderful young women we lost to MBC this year: a wonderful breast surgeon, a smart passionate pharmD, women just starting their lives. I am honored to have known them, their struggle & strength inspires me daily; I mourn what we have all lost
    Image
  • user avatar
    Hope Rugo
    @hoperugo
    Mar 5, 2023
    Very nice table of relative risks of breast cancer and associated germline mutations presented by susan Domchek at Miami BCC 2023 โฆ@gotoPERโฉ #MBCC2023 โฆ@OncoAlertโฉ
    Image
    14K
  • user avatar
    Hope Rugo
    @hoperugo
    Sep 18, 2021
    The data speaks for itself. Destiny breast 04: TDXd beats TDM1 in HER2+MBC. Longest PFS ever in this setting. OS trending better. Low ILD. A new SOC. @myESMO @OncoAlert #ESMO2021 @JavierCortesMD
    Image
  • user avatar
    Hope Rugo
    @hoperugo
    Oct 17, 2025
    #esmo2025 remarkable study at a single center in India showed marked improvement in pCR with very low dose pembro vs none plus chemo in very high risk ES TNBC. Improving access worldwide to effective therapy!
    Image
    Image
    Image
    Image
    18K
  • user avatar
    Hope Rugo
    @hoperugo
    Sep 15, 2024
    Peter Schmid presents the OS data from KN522 #ESMO24 publl now in NEJM. >6 year FU: 9% EFS benefit, 5% โฌ†๏ธOS with pembro pre/post op for TNBC. Pts with PCR had 95% survival +/-pembro but 6% โฌ†๏ธOS in nonPCR + pembro. Safety same. Huge advance for TNBC. Need biomarkers! @OncoAlert
    Image
    Image
    Image
    Image
    18K
  • user avatar
    Hope Rugo
    @hoperugo
    Aug 9, 2022
    Important paper and remarkable results. Just had a dramatic response in a patient with HER2 low disease in brain and LM, started T-DXd after ASCO, have not seen anything like this before. Very impressive. @OncoAlert
    user avatar
    Paolo Tarantino
    @PTarantinoMD
    Aug 8, 2022
    Does T-DXd work in HER2+ BC active brain metastases? Pretty clear answer in the below waterfall plot from #TUXEDO1 phase 2 trial, now published on @NatureMedicine. Impressive IC-ORR of 73%, mPFS 14 months, QoL maintained during Rx. Congrats to the authors! nature.com/articles/s4159โ€ฆ
    Image
  • user avatar
    Hope Rugo
    @hoperugo
    Sep 18, 2021
    A new treatment paradigm for metastatic HER2+ BC. Nice discussion of destiny breast 04 by Shanu Modi. โฆ@OncoAlertโฉ โฆ@myESMOโฉ #esmo2021
    Image
  • user avatar
    Hope Rugo
    @hoperugo
    Aug 13, 2021
    Feedback? Interested in your thoughts - first draft! Ongoing trials not included.... @OncoAlert @UCSFCancer
    Image
  • user avatar
    Hope Rugo
    @hoperugo
    Feb 7, 2022
    Nice summary by Harbeck Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer thebreastonline.com/article/S0960-โ€ฆ @OncoAlert
    Image
  • user avatar
    Hope Rugo
    @hoperugo
    Sep 4, 2022
    And now improved OS as well - to be presented at #ESMO22! A great team effort. ADCs are the chemo for the future - and that future is now. @UCSFCancer @OncoAlert
    user avatar
    OncLive.com
    @OncLive
    Sep 2, 2022
    Sacituzumab Govitecan Provides PFS Benefit Vs Chemotherapy in HR+/HER2โ€“ Breast Cancer @hoperugo @JCO_ASCO #bcsm ow.ly/t8gV50Kz7bz
  • Second interim analysis shows significant OS benefit! Trodelvyยฎ Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study. โฆ@OncoAlertโฉ gilead.com/news-and-pressโ€ฆ
  • user avatar
    Hope Rugo
    @hoperugo
    Dec 7, 2021
    #SABCS21 here we come! Excited for the plenary in the morning and hoping I can stay on time for my discussion! Happy to see the friends who were able to attend. @OncoAlert
    Image

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms of Service|Privacy Policy|Cookie Policy|Accessibility|Ads info|ยฉ 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up
Advertisement
Advertisement